This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main goal of this study is to find out whether taking a treatment with an estrogen hormone in addition to Vitamin D and Calcium will protect subjects from losing bone strength (osteoporosis). In patients with prostate cancer who do not have spread of the cancer to the bones, the bones can still become weak from the use of treatments for prostate cancer such as castration (surgical removal of the testicles) or medications such as Lupron (leuprolide) and Zoladex (goserelin). All these treatments lower the amount of testosterone in the body which is important to prevent osteoporosis. Other goals of the study are to gain understanding of how estrogens might prevent loss of bone strength, and to find out what the side effects of estrogen are as well as whether it can relieve hot flashes. Subjects will be randomized to receive Estradiol or Placebo for a period of up to 12 months. Both arms will receive Vitamin D and Calcium in the same doses.
Showing the most recent 10 out of 94 publications
